证券代码：002566 证券简称：益盛药业 公告编号：2025-043 吉林省集安益盛药业股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下称"公司"）第九届董事会第三次 会议通知以当面送达、电话、邮件的方式于2025年10月17日向各董事发出，会议 于2025年10月24日以现场会议的方式在公司四楼会议室召开。会议应参加审议董 事9人，实际参加审议董事9人。本次会议的召开符合《公司法》及《公司章程》 的规定，合法有效。会议由董事长张益胜先生主持，审议并通过了如下议案： 一、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《2025年 第三季度报告》。 《2025年第三季度报告》详见巨潮资讯网（www.cninfo.com.cn）及《中国 证券报》、《上海证券报》、《证券时报》。 二、会议以9票同意、0票反对、0票弃权的表决结果，审议通过了《关于向 银行申请流动资金贷款的议案》。 《关于取消监事会并修订<公司章程>及修订、制定公司部分治理制度的公告》 详见巨潮资讯网（ww ...

Financial Performance - The company's revenue for Q3 2025 was ¥148,369,275.22, a decrease of 5.93% compared to the same period last year[4] - Net profit attributable to shareholders increased by 112.12% to ¥5,364,562.46, while net profit excluding non-recurring gains and losses decreased by 37.81% to ¥12,561,156.24[4] - Basic and diluted earnings per share were both ¥0.0162, reflecting an increase of 113.16% year-on-year[4] - Total operating revenue decreased to ¥476,195,233.12 from ¥505,560,683.83, representing a decline of approximately 5.7% year-over-year[20] - Net profit for the period was ¥24,418,791.01, down from ¥33,402,435.53, reflecting a decrease of approximately 26.9% year-over-year[22] - Earnings per share (EPS) decreased to ¥0.0729 from ¥0.1084, a decline of about 32.7% year-over-year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,983,619,110.84, a 0.44% increase from the previous year[5] - The company's total assets as of September 30, 2025, amounted to CNY 2,983,619,110.84, an increase from CNY 2,970,654,385.62 at the beginning of the period[16] - Current assets increased to CNY 2,414,642,306.45 from CNY 2,375,780,311.63, reflecting a growth of approximately 1.12%[17] - Total liabilities increased to ¥658,861,084.23 from ¥637,219,990.02, reflecting an increase of approximately 3.9% year-over-year[18] - The company's total liabilities increased, with current liabilities including accounts payable decreasing to CNY 10,663,685.39 from CNY 13,001,831.67, a decline of approximately 18%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,548,844.03, showing a slight increase of 0.91%[4] - Cash inflow from operating activities totaled ¥535,723,149.74, down from ¥600,832,070.69, indicating a decrease of approximately 10.8% year-over-year[23] - The net cash flow from operating activities was $41,548,844.03, showing a slight increase from $41,175,388.85 in the previous period[24] - The total cash outflow from operating activities was $494,174,305.71, down from $559,656,681.84 in the prior period[24] Investment and Financial Activities - The company reported a significant increase in investment income, which rose by 141.28% to ¥11,565,434.04 due to gains from the disposal of financial assets[8] - Financial expenses increased to ¥9,608,017.34 from ¥4,351,479.19, representing an increase of approximately 120.5% year-over-year[21] - Cash inflow from investment activities totaled $461,881,788.97, significantly up from $105,257,875.37 in the prior period[24] - The company received $450,000,000.00 from investment recoveries, a significant increase from $100,000,000.00 previously[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,569, with the largest shareholder holding 39.08% of the shares[10] - The company is addressing issues related to shareholding transparency and has implemented a plan to reduce the number of shares held in trust[13] - The company reported that certain shareholders have resolved their shareholding issues, ensuring compliance with regulatory requirements[14] - The company is committed to protecting the interests of minority investors during the share reduction process[14] Expenses - Total operating costs decreased to ¥461,908,412.48 from ¥487,965,647.77, a reduction of about 5.3% year-over-year[20] - Research and development expenses were ¥11,554,503.24, down from ¥14,377,485.51, a decrease of about 19.5% year-over-year[21] - The company paid $87,882,445.89 to employees, a decrease from $110,162,283.72 in the previous period[24] - The company’s cash outflow for taxes was $68,038,842.62, down from $75,704,346.51 in the prior period[24]

（文章来源：证券日报） 证券日报网讯益盛药业10月14日在互动平台回答投资者提问时表示，截至2025年10月10日，公司股东总 户数19658户。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

证券日报网讯益盛药业（002566）9月22日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东总户数为19，709户。 ...

Core Insights - Yisheng Pharmaceutical reported that as of September 10, 2025, the total number of shareholders is 20,399 [2] Company Summary - Yisheng Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is tracking its shareholder base, indicating a focus on investor relations and transparency [2]

Summary of Key Points Core Viewpoint - Yisheng Pharmaceutical reported a decrease in the number of shareholders and a decline in both revenue and net profit for the first half of the year, indicating potential challenges for the company moving forward [2]. Shareholder Information - As of August 31, the number of shareholders for Yisheng Pharmaceutical was 20,554, a decrease of 1,366 from the previous period (August 20), representing a decline of 6.23% [2]. Stock Performance - The closing price of Yisheng Pharmaceutical was 8.08 yuan, reflecting an increase of 1.38%. However, since the concentration of shares began, the stock price has cumulatively decreased by 6.05%, with 2 days of increase and 6 days of decrease during the reporting period [2]. Financial Performance - For the first half of the year, Yisheng Pharmaceutical achieved a revenue of 328 million yuan, a year-on-year decrease of 5.75%. The net profit was 18.76 million yuan, down 43.71% year-on-year. The basic earnings per share were 0.0567 yuan, and the weighted average return on equity was 0.84% [2].

Group 1 - A new company named Hangzhou Youxuan Youyi Health Management Co., Ltd. has been established, with Cui Dongsheng as the legal representative [1] - The company's business scope includes the acquisition of primary agricultural products, sales of agricultural and sideline products, wholesale of edible agricultural products, and retail of edible agricultural products [1] - The company is jointly held by Jiao Ge Peng You Xuan Technology Co., Ltd. and Yisheng Pharmaceutical (002566) among others [1]

Financial Performance - Yisheng Pharmaceutical (002566) reported a net profit decline of 43.71% year-on-year for the first half of 2025, with total revenue of 328 million yuan, down 5.75% from the previous year [1] - The gross profit margin decreased to 75.15%, a drop of 2.02% year-on-year, while the net profit margin fell to 6.05%, down 36.94% [1] - The company’s total expenses (selling, administrative, and financial) reached 219 million yuan, accounting for 66.83% of revenue, an increase of 2.16% year-on-year [1] Cash Flow and Financial Ratios - The company experienced a significant increase in financial expenses by 502.37% due to reduced interest income [3] - The net cash flow from investment activities increased by 100.86%, attributed to higher cash recovered from investments compared to the previous year [3] - The company’s return on invested capital (ROIC) was reported at 2.08%, indicating historically weak capital returns [3] Accounts Receivable and Inventory - The accounts receivable to profit ratio reached 312.96%, suggesting potential issues with cash collection [4] - The inventory to revenue ratio stood at 241.32%, indicating a high level of inventory relative to sales [4] Strategic Focus - The company plans to increase its research and development efforts to meet market demands, addressing concerns about the lack of new product development in traditional Chinese medicine [5]

Core Points - The company has not distributed cash dividends or bonus shares during the reporting period [3] - The company has implemented a rectification plan to address issues related to shareholding by proxy, ensuring accurate disclosure of shareholder information [5] - The board of directors and supervisory board have both approved the 2025 semi-annual report, confirming its compliance with legal and regulatory requirements [10][12] Company Overview - The company is identified as Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. with the stock code 002566 [1] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6][7] Financial Information - The company has not reported any preferred shareholders or related data during the reporting period [8] - The company has not issued any bonds that are still in existence as of the date of the semi-annual report [9]